149 related articles for article (PubMed ID: 17826092)
21. The development of 2-benzimidazole substituted pyrimidine based inhibitors of lymphocyte specific kinase (Lck).
Sabat M; VanRens JC; Laufersweiler MJ; Brugel TA; Maier J; Golebiowski A; De B; Easwaran V; Hsieh LC; Walter RL; Mekel MJ; Evdokimov A; Janusz MJ
Bioorg Med Chem Lett; 2006 Dec; 16(23):5973-7. PubMed ID: 16997556
[TBL] [Abstract][Full Text] [Related]
22. Pyrazolo-pyrimidines: a novel heterocyclic scaffold for potent and selective p38 alpha inhibitors.
Das J; Moquin RV; Pitt S; Zhang R; Shen DR; McIntyre KW; Gillooly K; Doweyko AM; Sack JS; Zhang H; Kiefer SE; Kish K; McKinnon M; Barrish JC; Dodd JH; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2652-7. PubMed ID: 18359226
[TBL] [Abstract][Full Text] [Related]
23. Synthesis, initial SAR and biological evaluation of 1,6-dihydroimidazo[4,5-d]pyrrolo[2,3-b]pyridin-4-amine derived inhibitors of IkappaB kinase.
Kempson J; Guo J; Das J; Moquin RV; Spergel SH; Watterson SH; Langevine CM; Dyckman AJ; Pattoli M; Burke JR; Yang X; Gillooly KM; McIntyre KW; Chen L; Dodd JH; McKinnon M; Barrish JC; Pitts WJ
Bioorg Med Chem Lett; 2009 May; 19(10):2646-9. PubMed ID: 19376699
[TBL] [Abstract][Full Text] [Related]
24. Identification and Preliminary SAR Analysis of Novel Type-I Inhibitors of TIE-2 via Structure-Based Virtual Screening and Biological Evaluation in in vitro Models.
Pan P; Tian S; Sun H; Kong X; Zhou W; Li D; Li Y; Hou T
J Chem Inf Model; 2015 Dec; 55(12):2693-704. PubMed ID: 26618892
[TBL] [Abstract][Full Text] [Related]
25. Discovery of imidazo[1,2-b]pyridazine derivatives as IKKbeta inhibitors. Part 1: Hit-to-lead study and structure-activity relationship.
Shimizu H; Tanaka S; Toki T; Yasumatsu I; Akimoto T; Morishita K; Yamasaki T; Yasukochi T; Iimura S
Bioorg Med Chem Lett; 2010 Sep; 20(17):5113-8. PubMed ID: 20675134
[TBL] [Abstract][Full Text] [Related]
26. Aza-stilbenes as potent and selective c-RAF inhibitors.
McDonald O; Lackey K; Davis-Ward R; Wood E; Samano V; Maloney P; Deanda F; Hunter R
Bioorg Med Chem Lett; 2006 Oct; 16(20):5378-83. PubMed ID: 16890436
[TBL] [Abstract][Full Text] [Related]
27. 1,4-dihydropyrazolo[4,3-d]imidazole phenyl derivatives: a novel type II Raf kinase inhibitors.
Yu H; Jung Y; Kim H; Lee J; Oh CH; Yoo KH; Sim T; Hah JM
Bioorg Med Chem Lett; 2010 Jun; 20(12):3805-8. PubMed ID: 20466542
[TBL] [Abstract][Full Text] [Related]
28. Entry into a new class of protein kinase inhibitors by pseudo ring design.
Furet P; Caravatti G; Guagnano V; Lang M; Meyer T; Schoepfer J
Bioorg Med Chem Lett; 2008 Feb; 18(3):897-900. PubMed ID: 18248988
[TBL] [Abstract][Full Text] [Related]
29. Benzo[c][2,7]naphthyridines as inhibitors of PDK-1.
Kim KH; Wissner A; Floyd MB; Fraser HL; Wang YD; Dushin RG; Hu Y; Olland A; Guo B; Arndt K
Bioorg Med Chem Lett; 2009 Sep; 19(17):5225-8. PubMed ID: 19628388
[TBL] [Abstract][Full Text] [Related]
30. Design, synthesis, and structure-activity relationships of aminopyridine N-oxides, a novel scaffold for the potent and selective inhibition of p38 mitogen activated protein kinase.
Lumeras W; Caturla F; Vidal L; Esteve C; Balagué C; Orellana A; Domínguez M; Roca R; Huerta JM; Godessart N; Vidal B
J Med Chem; 2009 Sep; 52(17):5531-45. PubMed ID: 19678708
[TBL] [Abstract][Full Text] [Related]
31. 5-Vinyl-3-pyridinecarbonitrile inhibitors of PKCtheta: optimization of enzymatic and functional activity.
Tumey LN; Bhagirath N; Brennan A; Brooijmans N; Lee J; Yang X; Boschelli DH
Bioorg Med Chem; 2009 Dec; 17(23):7933-48. PubMed ID: 19884013
[TBL] [Abstract][Full Text] [Related]
32. Design and effective synthesis of novel templates, 3,7-diphenyl-4-amino-thieno and furo-[3,2-c]pyridines as protein kinase inhibitors and in vitro evaluation targeting angiogenetic kinases.
Miyazaki Y; Nakano M; Sato H; Truesdale AT; Stuart JD; Nartey EN; Hightower KE; Kane-Carson L
Bioorg Med Chem Lett; 2007 Jan; 17(1):250-4. PubMed ID: 17027260
[TBL] [Abstract][Full Text] [Related]
33. Synthesis and biological evaluation of 1,2,4-trisubstituted imidazoles and 1,3,5-trisubstituted pyrazoles as inhibitors of transforming growth factor beta type 1 receptor (ALK5).
Li X; Wang L; Long L; Xiao J; Hu Y; Li S
Bioorg Med Chem Lett; 2009 Aug; 19(16):4868-72. PubMed ID: 19616940
[TBL] [Abstract][Full Text] [Related]
34. Discovery of 6-aryl-7-alkoxyisoquinoline inhibitors of IkappaB kinase-beta (IKK-beta).
Christopher JA; Bamborough P; Alder C; Campbell A; Cutler GJ; Down K; Hamadi AM; Jolly AM; Kerns JK; Lucas FS; Mellor GW; Miller DD; Morse MA; Pancholi KD; Rumsey W; Solanke YE; Williamson R
J Med Chem; 2009 May; 52(9):3098-102. PubMed ID: 19348415
[TBL] [Abstract][Full Text] [Related]
35. Dual binding site inhibitors of B-RAF kinase.
Wolin RL; Bembenek SD; Wei J; Crawford S; Lundeen K; Brunmark A; Karlsson L; Edwards JP; Blevitt JM
Bioorg Med Chem Lett; 2008 May; 18(9):2825-9. PubMed ID: 18434146
[TBL] [Abstract][Full Text] [Related]
36. 4-Anilino-7-alkenylquinoline-3-carbonitriles as potent MEK1 kinase inhibitors.
Berger DM; Dutia M; Powell D; Floyd MB; Torres N; Mallon R; Wojciechowicz D; Kim S; Feldberg L; Collins K; Chaudhary I
Bioorg Med Chem; 2008 Oct; 16(20):9202-11. PubMed ID: 18815050
[TBL] [Abstract][Full Text] [Related]
37. Isothiazolopyrimidines and isoxazolopyrimidines as novel multi-targeted inhibitors of receptor tyrosine kinases.
Ji Z; Ahmed AA; Albert DH; Bouska JJ; Bousquet PF; Cunha GA; Glaser KB; Guo J; Li J; Marcotte PA; Moskey MD; Pease LJ; Stewart KD; Yates M; Davidsen SK; Michaelides MR
Bioorg Med Chem Lett; 2006 Aug; 16(16):4326-30. PubMed ID: 16735117
[TBL] [Abstract][Full Text] [Related]
38. Discovery of aryl aminoquinazoline pyridones as potent, selective, and orally efficacious inhibitors of receptor tyrosine kinase c-Kit.
Hu E; Tasker A; White RD; Kunz RK; Human J; Chen N; Bürli R; Hungate R; Novak P; Itano A; Zhang X; Yu V; Nguyen Y; Tudor Y; Plant M; Flynn S; Xu Y; Meagher KL; Whittington DA; Ng GY
J Med Chem; 2008 Jun; 51(11):3065-8. PubMed ID: 18447379
[TBL] [Abstract][Full Text] [Related]
39. Discovery of potent, selective and orally bioavailable imidazo[1,5-a]pyrazine derived ACK1 inhibitors.
Jin M; Wang J; Kleinberg A; Kadalbajoo M; Siu KW; Cooke A; Bittner MA; Yao Y; Thelemann A; Ji Q; Bhagwat S; Mulvihill KM; Rechka JA; Pachter JA; Crew AP; Epstein D; Mulvihill MJ
Bioorg Med Chem Lett; 2013 Feb; 23(4):979-84. PubMed ID: 23317569
[TBL] [Abstract][Full Text] [Related]
40. Development of pyridopyrimidines as potent Akt1/2 inhibitors.
Wu Z; Hartnett JC; Neilson LA; Robinson RG; Fu S; Barnett SF; Defeo-Jones D; Jones RE; Kral AM; Huber HE; Hartman GD; Bilodeau MT
Bioorg Med Chem Lett; 2008 Feb; 18(4):1274-9. PubMed ID: 18249537
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]